In 1887, William McLaren Bristol and John Ripley Myers founded a company with a simple yet powerful vision: to bring better health solutions to patients who needed them most. What began as Clinton Pharmaceutical Company has evolved into Bristol Myers Squibb, a global biopharmaceutical leader transforming patients' lives through science for over 135 years. The company's journey has been marked by breakthrough innovations that have redefined treatment paradigms, from pioneering cardiovascular therapies to revolutionizing cancer care with immunotherapy.
Today, Bristol Myers Squibb operates at the forefront of scientific discovery, combining the reach and resources of a major pharmaceutical company with the entrepreneurial spirit of a biotech firm. Their unique BioPharma strategy drives innovation across oncology, hematology, immunology, cardiology, and fibrosis - disease areas where patients need transformational medicines most. With approximately 32,500 employees worldwide and operations spanning more than 100 countries, BMS delivers innovative medicines that help patients prevail over serious diseases. The company's commitment extends beyond medicine through the Bristol Myers Squibb Foundation, which promotes health equity and supports vulnerable populations globally. From cell therapy breakthroughs to advancing health equity, BMS continues to push the boundaries of what's possible in patient care.
